CHARLTON, STEVEN JOHN,LEBLANC, CATHERINE,MCKEOWN, STEPHEN CARL
申请号：
PE2013000058
公开号：
PE20130404A1
申请日:
2011.07.14
申请国别(地区):
PE
年份:
2013
代理人:
摘要：
It refers to non circulating formula compounds, where a is n or Cr ',Where R 'is h or asphalt (C1-C8), which can be replaced by halogen； R1 is h, which can be replaced by halogen (C1-C8), etc.； R2 is h, - X -.-S（o）2-W-X-YAmong them, W and X are optional hydrocarbon groups (C1-C8) which are replaced by hydroxyl, halogenated or pitch (C1-C4)；This is anthrax, tetraethyl benzene, aminobenzene, etc.； R2A is h； R2 and R2A are oxo； R3 and R4 are h, alcoxyl (C1-C4),Among other things, R5 is a tar (C1-C8),Alcoxyl（C1-C8），Arilo（C6-C14），R6 is arilo (C6-C14), among other things,1. Asphalt (c0-c4) - 4-14 members and others； The most popular compounds are: acid 7 - (6,7-diphenyl-3,4-dihydro-1,8-nafeldin-1 (2H) - one three heptane； acid 7 - (2,3-diphenyl-7,8-dihydro-pyridan [3,2-b] pyridine-5 (6h) - one heptane； and other compounds. He also mentioned a pharmaceutical composer These compounds are effective drugs for prostate secretion inhibitors (IP) in the treatment of pulmonary hypertension (PAH).pulmonary fibrosisSE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (Ia) DONDE A ES N O CR', EN DONDE R' ES H O ALQUILO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HALOGENO； R1 ES H, ALQUILO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH, ENTRE OTROS； R2 ES H, -X-Y-, -S(O)2-W-X-Y-, ENTRE OTROS, EN DONDE W Y X SON ALQUILENO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HIDROXILO, HALOGENO O ALQUILO(C1-C4)； Y ES CARBOXILO, TETRAZOLILO, CARBAMOILO, ENTRE OTROS； R2a ES H； R2 Y R2a SON JUNTOS OXO； R3 Y R4 SON CADA UNO H, ALCOXILO(C1-C4), OH, CN, ENTRE OTROS； R5 ES ALQUILO(C1-C8), ALCOXILO(C1-C8), ARILO(C6-C14), ENTRE OTROS； R6 ES ARILO(C6-C14), ALQUILO(C0-C4)-HETEROARILO DE 4 A 14 MIEMBROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 7-(6,7-DIFENIL-3,4-DIHIDRO-1,8-NAFTIRIDIN-1(2H)-IL)-HEPTANOICO； ACIDO 7-(2,3-DIFENIL-7,8-DIHIDRO-PIRIDO[3,2-b]PIRAZIN-5(6H)-IL)-HEPTANOICO； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE PROSTACICLINA (IP) SIENDO
